The ultimate goal was to develop molecular diagnostic products that would predict the body's response to leading drugs in the treatment of colon and gastric cancer.
WangDon Yoo, CEO and President of GeneMatrix chose VARIAGENICS as a collaborative partner because, "they have the best platform and expertise in applying pharmacogenomics to all phases of drug and diagnostic development from discovery to commercialization.
"[1] December 2002, a multi-year contract agreement with IMPATH, a leading source of cancer information and analysis, was established to provide laboratory services for patients in South Korea.
IMPATH's expertise as well as its comprehensive service offerings will significantly enhance the ability of local physicians to assess treatment alternatives for cancer patients in our country.".
"The spray solvent system operates at the stage of washing a complex mixture of polymerase chain reaction (PCR) products, so that the oligonucleotides can be detected without sample treatment.